![]() |
CZC-54252
- 英文名称:CZC-54252
- 品牌:WYTSCI
- 产地:进口
- 型号:1MG
- 货号:WT-AY-B10310
- cas:1191911-27-9
- 价格: ¥1/mg
- 发布日期: 2025-04-10
- 更新日期: 2025-05-23
产品详请
产地 | 进口 |
品牌 | WYTSCI |
货号 | WT-AY-B10310 |
用途 | 科研检测 |
英文名称 | CZC-54252 |
包装规格 | 1MG |
CAS编号 | 1191911-27-9 |
别名 | CZC-54252 |
纯度 | 98+% |
分子式 | |
是否进口 | 是 |
纯度:98% by TLC,;NMR (Conforms)
分子式:C22H25ClN6O4S · HCl
分子量:541.46
溶剂:DMSO (50 mg/ml)
性状:Off-white solid
存储:-20°C
Activity (short version):LRRK2
Function / Pharmacology:Novel, potent and selective inhibitor of the leucine-rich repeat kinase-2 (LRRK2), IC50 = 1.28 nM. Also inhibits G2019S mutant LRRK2, IC50 = 1.85 nM1. Attenuates the neuronal damage elicited by the action of LRRK2 G2019S mutant in primary human neurons (EC50 = 1 nM)1. The G2019S mutant is a common mutation found in familial Parkinson’s disease patients2. Cell permeable.
分子式:C22H25ClN6O4S · HCl
分子量:541.46
溶剂:DMSO (50 mg/ml)
性状:Off-white solid
存储:-20°C
Activity (short version):LRRK2
Function / Pharmacology:Novel, potent and selective inhibitor of the leucine-rich repeat kinase-2 (LRRK2), IC50 = 1.28 nM. Also inhibits G2019S mutant LRRK2, IC50 = 1.85 nM1. Attenuates the neuronal damage elicited by the action of LRRK2 G2019S mutant in primary human neurons (EC50 = 1 nM)1. The G2019S mutant is a common mutation found in familial Parkinson’s disease patients2. Cell permeable.